- Review Article
- Infection
- Recommendation for use of a long-acting monoclonal antibody to prevent respiratory syncytial virus infection in infants and young children
-
Soo-Han Choi, Dong Hyun Kim, Jong Gyun Ahn, Ki Wook Yun, Byung-Wook Eun, Jin Lee, Jina Lee, Taek-Jin Lee, Hyunju Lee, Dae Sun Jo, Eun Young Cho, Hye-Kyung Cho, Young June Choe, Ui Yoon Choi, Yun-Kyung Kim; The Committee on Infectious Diseases of the Korean Pediatric Society
-
Clin Exp Pediatr. 2025;68(10):742-750. Published online September 3, 2025
-
|
To prevent respiratory syncytial virus (RSV)-associated lower respiratory tract infections, a single dose of nirsevimab, a long-acting monoclonal antibody, is recommended for all neonates born during the RSV season (October to March) and all infants younger than 6 months old at the start of the RSV season. Nirsevimab should be administered shortly after birth to neonates and just before or early in the season to infants entering their first RSV season. |
-
-
- Original Article
- Clinical manifestations of CNS infections caused by enterovirus type 71
-
Cheol Soon Choi, Yun Jung Choi, Ui Yoon Choi, Ji Whan Han, Dae Chul Jeong, Hyun Hee Kim, Jong Hyun Kim, Jin Han Kang
-
Clin Exp Pediatr. 2011;54(1):11-16. Published online January 31, 2011
-
|
|
Purpose Enterovirus 71, one of the enteroviruses that are responsible for both hand-foot-and-mouth disease and herpangina, can cause neural injury. During periods of endemic spread of hand-foot-andmouth disease caused by enterovirus 71, CNS infections are also frequently diagnosed and may lead to increased complications from neural injury, as well as death. We present the results of our epidemiologic research on the... |
-
-
|
